Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × Clear all

Phase

Status

Not yet recruiting 2 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 767 Carcinoma, Non-Small-Cell Lung 501 Neoplasms 466 Prostatic Neoplasms 446 Colorectal Neoplasms 277 Lung Neoplasms 271 Multiple Myeloma 268 Neoplasm Metastasis 226 Melanoma 222 Ovarian Neoplasms 201 Pancreatic Neoplasms 195 Leukemia, Myeloid, Acute 192 Squamous Cell Carcinoma of Head and Neck 158 Recurrence 154 Lymphoma 146 Brain Neoplasms 146 Stomach Neoplasms 145 Glioblastoma 145 Carcinoma, Renal Cell 145 Carcinoma, Hepatocellular 140 Head and Neck Neoplasms 131 Lymphoma, Non-Hodgkin 130 Leukemia, Lymphocytic, Chronic, B-Cell 125 Precursor Cell Lymphoblastic Leukemia-Lymphoma 124 Triple Negative Breast Neoplasms 122 Uterine Cervical Neoplasms 114 Urinary Bladder Neoplasms 111 Lymphoma, Large B-Cell, Diffuse 108 Colonic Neoplasms 107 Hematologic Neoplasms 106

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡